Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette

You may also be interested in...



Boston Scientific nabs French coverage

The French government will pay for Taxus Liberté after the drug-eluting stent received reimbursement approval on Feb. 15. The firm notes that the paclitaxel-eluting stent will now be available to patients at both private and public hospitals in France. The device was CE marked in September 2005. According to the firm, France was slow to adopt and reimburse the original Taxus stent (1"The Gray Sheet" Feb. 9, 2004, p. 20)...

Boston Scientific nabs French coverage

The French government will pay for Taxus Liberté after the drug-eluting stent received reimbursement approval on Feb. 15. The firm notes that the paclitaxel-eluting stent will now be available to patients at both private and public hospitals in France. The device was CE marked in September 2005. According to the firm, France was slow to adopt and reimburse the original Taxus stent (1"The Gray Sheet" Feb. 9, 2004, p. 20)...

Boston Sci/Nitromed NO more

Five-year R&D pact between device powerhouse and Lexington, Mass.-based pharmaceutical company expires without renewal Dec. 31. Boston Scientific and Nitromed were investigating the latter's nitric oxide (NO) technology as a potential complement to paclitaxel in Taxus stents (1"The Gray Sheet" Feb. 9, 2004, p. 20). A Nitromed rep described the exploratory project as "fruitful" but did not cite any resulting product development. The company is seeking other alliances in the device industry for development of its NO technology, which the firm believes could enhance current treatments for cardiovascular disease, pain and asthma...

Related Content

UsernamePublicRestriction

Register

MT019694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel